Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST) announced its participation in the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. The conference will facilitate investor meetings and a live webcast is accessible on the Oyster Point Pharma website.

The company is dedicated to developing first-in-class therapies for ocular surface diseases. Its lead candidate, OC-01 nasal spray, aims to treat dry eye disease and utilizes a novel mechanism to stimulate natural tear production.

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET, and host investor meetings.

To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.

About Oyster Point Pharma, Inc.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any indication in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com

Media Contact: 
Sheryl Seapy
W2O Group 
(213) 262-9390 
sseapy@w2ogroup.com

FAQ

When is Oyster Point Pharma participating in the J.P. Morgan Healthcare Conference?

Oyster Point Pharma will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET.

How can I access the Oyster Point Pharma conference webcast?

The live webcast of the event can be accessed through the 'Investors and News' section of the Oyster Point Pharma website.

What is OC-01 nasal spray developed by Oyster Point Pharma?

OC-01 nasal spray is an investigational drug designed to treat dry eye disease by stimulating natural tear production through the trigeminal parasympathetic pathway.

Is OC-01 nasal spray approved for any use?

No, OC-01 nasal spray is still an investigational new drug and has not been approved for any indication in any country.

What is the primary focus of Oyster Point Pharma?

Oyster Point Pharma focuses on discovering and developing pharmaceutical therapies for ocular surface diseases.